J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.

Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas ...

Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, Johnson & Johnson announced in a press release. Icotrokinra (Icotyde) is the ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

When you have psoriasis — a skin disease that typically causes thick, itchy, scaly, or discolored patches of skin — finding a treatment that works for you can be a challenge. Luckily, there are more ...

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.